| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/28/2005 | US6911211 Pharmaceutical and cosmetic carrier or composition for topical application |
| 06/28/2005 | US6911197 Water soluble and non-peptidic polymer backbone having terminal carbon, such as a poly(alkylene glycol), terminal carbon of polymer backbone being directly bonded to nitrogen atom of N-maleimidyl moiety without linking group therebetween |
| 06/28/2005 | CA2402300C Fluorocarbon aerosol medicaments |
| 06/28/2005 | CA2360557C Biodegradable and thermosensitive polyphosphazenes and their preparation method |
| 06/28/2005 | CA2317411C Controlled release delivery of peptide or protein |
| 06/28/2005 | CA2271196C Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability |
| 06/28/2005 | CA2138110C Cosmetic and/or dermatologic composition containing salicylic acid derivatives and process for their solubilization |
| 06/23/2005 | WO2005056641A1 Coordination complex of diaminocyclohexaneplatinum(ii) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same |
| 06/23/2005 | WO2005056636A2 Method of preparing maleimide functionalized polymers |
| 06/23/2005 | WO2005056607A1 PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN |
| 06/23/2005 | WO2005056572A2 Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof |
| 06/23/2005 | WO2005056038A1 Pharmaceutical compositions and methods for insulin treatment |
| 06/23/2005 | WO2005056008A1 Intranasal compositions |
| 06/23/2005 | WO2005055989A1 Drug-containing grains and solid preparation containing the grains |
| 06/23/2005 | WO2005055980A2 Polymalic acid-based multifunctional drug delivery system |
| 06/23/2005 | WO2005055976A2 Powder containing low-molecular dextran and method for producing the same |
| 06/23/2005 | WO2005055975A2 Uv-stable semi-solid transdermal systems comprising a photosensitive active ingredient and a uv absorber |
| 06/23/2005 | WO2005055949A2 Sustained release preparations composed of biocompatible complex microparticles |
| 06/23/2005 | WO2005055924A2 Skin adherent hydrogels |
| 06/23/2005 | WO2005055808A2 Compositions and methods to diagnose and treat lung cancer |
| 06/23/2005 | WO2005027873A3 Therapeutic aminoglycoside-containing hydrogel nanoparticles |
| 06/23/2005 | WO2005018602A3 Method for the production of effervescent granules in a vacuum |
| 06/23/2005 | WO2004113383A3 Pegylated soluble gp130-dimers useful as a medicament |
| 06/23/2005 | US20050137592 Vessel sealing instrument |
| 06/23/2005 | US20050137384 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| 06/23/2005 | US20050137334 Composite nanospheres and their conjugates with biomolecules |
| 06/23/2005 | US20050137276 Skin contact adhesives; electricity interface for disposable medical devices; shelf life; storage stability; protective coatings |
| 06/23/2005 | US20050137246 Organic amine salts of glutamic acid derivatives and their application |
| 06/23/2005 | US20050137167 Inhibiting FGF growth factor with heparins; antitumor agents; angiogenesis inhibitor; antidiabetic agent treating diabetic retinopathy; antiinflammatory agent; treating retrolenticular fibroplasia, psoriasis, restenosis after angioplasty and after coronary by-pass; chemical intermediates; drug delivery |
| 06/23/2005 | US20050137164 comprising topical mixtures of non-steroidal anti-inflammatory drug (NSAID) and carriers |
| 06/23/2005 | US20050137155 RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
| 06/23/2005 | US20050137153 RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
| 06/23/2005 | US20050137148 treating an infectious disease associated with narrowing or obstruction of a body passageway by delivering to an external portion of the body passageway an antibiotic; infections such as pelvic inflammatory disease, urethritis, or tuberculosis |
| 06/23/2005 | US20050137133 nonimmunogenic water soluble polypeptides coupled to hydrophilic polymers, used as thrombopoietin agonist for the treatment of thrombocytopenia; blood disorders |
| 06/23/2005 | US20050136437 Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| 06/23/2005 | US20050136436 Double stranded short interfering nucleic acid for use in the treatment of schizophrenia; gene expression inhibition and hairpin loops |
| 06/23/2005 | US20050136133 Administering an anti-allergy composition of a wood-vinegar distilled solution, colorless and transparent |
| 06/23/2005 | US20050136128 Dry powders of metal-containing compounds |
| 06/23/2005 | US20050136122 Preparing and using crosslinked, water insoluble, hydrated hyaluronic acid gel particles; in vivo biostability and mechanical properties, usability; ease of injection through fine needles |
| 06/23/2005 | US20050136120 Intravenous pharmaceutical form of administration |
| 06/23/2005 | US20050136119 Liquid matrix containing drug, a first flavoring agent, and a plurality of particles comprising a second flavoring agent; adjusted color, flavor, sweetness, texture |
| 06/23/2005 | US20050136113 Dosage form comprising a semipermeable wall defining a cavity having an exit orifice; expandable layer; flow control agent; sustained release push delivery devices having high drug loading with minimized residue |
| 06/23/2005 | US20050136105 Consumer customized dosage forms |
| 06/23/2005 | US20050136103 Compositions capable of facilitating penetration across a biological barrier |
| 06/23/2005 | US20050136102 Enhanced transport using membrane disruptive agents |
| 06/23/2005 | US20050136096 Minimizes the exposure of the medicant in the film to moisture, heat, and shear during the manufacturing process; renders the film palatable to a pet |
| 06/23/2005 | US20050136087 Controlling the amount of an already existing antioxidant or stabilizer; decrease or to prevent the formation of acid/base catalyzed decomposition of the active ingredient |
| 06/23/2005 | US20050136085 Panthenol and natural organic extracts for reducing skin irritation |
| 06/23/2005 | US20050136081 Storage stability and high viscosity |
| 06/23/2005 | US20050136047 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 06/23/2005 | US20050136041 Transgenic cell comprising nucleotide sequences coding erythropoietin and/or glucagon-like peptides for use in treatment and prevention of blood and metabolic disorders; somatic and germ cell gene therapy; tissue engineering |
| 06/23/2005 | US20050136032 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 06/23/2005 | US20050136031 Chemically modified small molecules |
| 06/23/2005 | US20050136010 Treatment of chronic obstructive pulmonary disease, by administering inhalant with particulate carrier or diluent selecting from saccharide, a sugar alcohol or lactose, in an amount of from 400 mu g to 5000 mu g per mu g of active ingredient |
| 06/23/2005 | US20050136001 Fluorinated carbohydrate conjugates |
| 06/23/2005 | DE10356248A1 Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden A pharmaceutical composition for the treatment of rhinitis |
| 06/23/2005 | DE10355559A1 Transskin Transskin |
| 06/23/2005 | DE10355251A1 Water-based pharmaceutical preparation for treatment of tumors has active ingredient effective against receptor of endothelial growth factor receptor |
| 06/23/2005 | DE10353792A1 Ointment for treating or preventing inflammatory reactions comprises an ointment base and an emulsion comprising silicone, emulsifier, salt solution and dimethyl sulfoxide |
| 06/23/2005 | CA2548559A1 Intranasal compositions comprising granisetron and chitosan |
| 06/23/2005 | CA2548132A1 Powder containing low-molecular dextran and method for producing the same |
| 06/22/2005 | EP1544305A1 Adapter for docking a substance to the cell wall |
| 06/22/2005 | EP1543841A1 Soild nano pharmaceutical formulation and preparation method thereof |
| 06/22/2005 | EP1543840A1 Drug absorbability improving agents |
| 06/22/2005 | EP1543839A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 06/22/2005 | EP1543831A1 Pregabalin composition |
| 06/22/2005 | EP1543830A1 Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides |
| 06/22/2005 | EP1543829A1 Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides |
| 06/22/2005 | EP1543827A1 Emulsion of perfluororganic compounds exhibiting gas-transport properties, a surface-active agent for said emulsion and method for the production thereof |
| 06/22/2005 | EP1543826A1 Concentrated aqueous solution of ambroxol |
| 06/22/2005 | EP1543732A1 Enzyme preparation and process for producing food using the same |
| 06/22/2005 | EP1543324A2 Methods and compositions for grafting functional loops into a protein |
| 06/22/2005 | EP1543105A1 New mutant strains of pseudomonas fluorescens and variants thereof, methods for their production, and uses thereof in alginate production |
| 06/22/2005 | EP1543063A1 Drug delivery |
| 06/22/2005 | EP1543040A1 Solubilising polysaccharides substituted with hydrophilic and hydrophobic groups |
| 06/22/2005 | EP1542955A1 Alkoxylates exhibiting low residual alcohol content |
| 06/22/2005 | EP1542926A1 Methods and compounds for controlling the morphology and shrinkage of silica derived from polyol-modified silanes |
| 06/22/2005 | EP1542904A1 Process for producing metered dose inhaler formulations |
| 06/22/2005 | EP1542753A1 Pharmaceutical compositions |
| 06/22/2005 | EP1542729A1 Stable immunogenic product comprising antigenic heterocomplexes |
| 06/22/2005 | EP1542728A1 Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same |
| 06/22/2005 | EP1542727A2 Breath freshening and oral cleansing product |
| 06/22/2005 | EP1542723A2 Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| 06/22/2005 | EP1542712A2 Glp-1 formulations with protracted time action |
| 06/22/2005 | EP1542707A2 Compositions and methods for ligament growth and repair |
| 06/22/2005 | EP1542705A1 Anticoagulant composition |
| 06/22/2005 | EP1542695A1 Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer. |
| 06/22/2005 | EP1542671A1 Composition based on triethyl citrate for the treatment of bacterial infections of the skin |
| 06/22/2005 | EP1542668A2 Aripiprazole complex formulation and method |
| 06/22/2005 | EP1542666A1 Modafinil pharmaceutical compositions |
| 06/22/2005 | EP1542664A2 Methods and compositions for treatment of macular and retinal disease |
| 06/22/2005 | EP1542553A2 A chemical carrier based on a beta-limit dextrin |
| 06/22/2005 | EP1542531A1 Aqueous fludarabine phosphate composition |
| 06/22/2005 | EP1414299A4 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use |
| 06/22/2005 | EP1381611B1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 06/22/2005 | EP1305057B1 Microparticulate biomaterial composition of hyaluronic acid for medical use |
| 06/22/2005 | EP1231941B1 Tablets comprising micro-organisms and method for preparation of the tablets |
| 06/22/2005 | EP1171136B1 Immunomodulating compositions comprising urea derivatives for use in the treatment of inflammatory diseases |
| 06/22/2005 | EP1150717B1 Sustained release salts of pharmaceutically active peptides and their production |
| 06/22/2005 | EP1100542B1 Peg-urate oxidase conjugates and use thereof |